3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
240
Rectal Neoplasms
93
Colonic Neoplasms
91
Pancreatic Neoplasms
87
Stomach Neoplasms
68
Neoplasm Metastasis
47
Esophageal Neoplasms
41
Neoplasms
36
Small Cell Lung Carcinoma
29
Lung Neoplasms
29
Neuroblastoma
28
Glioblastoma
28
Glioma
27
Brain Neoplasms
26
Carcinoma, Non-Small-Cell Lung
22
Adenocarcinoma Of Esophagus
20
Gliosarcoma
19
Breast Neoplasms
18
Astrocytoma
18
Esophageal Squamous Cell Carcinoma
17
Central Nervous System Neoplasms
17
Unspecified Adult Solid Tumor, Protocol Specific
16
Oligodendroglioma
13
Adenocarcinoma
13
Rhabdomyosarcoma
10
Gastrointestinal Neoplasms
10
Biliary Tract Neoplasms
10
Sarcoma
9
Gallbladder Neoplasms
9
Cholangiocarcinoma
9
Interventions
Cyclophosphamide
21
Cytarabine
15
blinatumomab
13
fludarabine
12
Azacitidine
10
venetoclax
9
fludarabine phosphate
9
Blood Specimen Collection
8
Methotrexate
7
Lenalidomide
7
Dexamethasone
7
Rituximab
6
Mercaptopurine
6
Daunorubicin
6
Vincristine
5
daratumumab
4
Whole-Body Irradiation
4
Melphalan
4
Etoposide
4
Busulfan
4
obinutuzumab
3
Radiotherapy
3
Neoadjuvant Therapy
3
Maintenance
3
Liquid Biopsy
3
Immunotherapy, Adoptive
3
Idarubicin
3
Granulocyte Colony-Stimulating Factor
3
Drug Therapy
3
Doxorubicin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasm, Residual
×
Irinotecan
×
Clear all
NCT05427669
2022-10-07
AFFORD
Sun Yat-sen University
Phase 3
Not yet recruiting
340 enrolled